In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Benoit You to discuss KELIM validation. Dr. You is a French medical oncologist at Lyon University Hospital, specialized in gynecological cancers, and the head of the drug development program of his institution (CITOHL-EPSILYON). Morever, he is the Director of a university research team involved in pharmacokinetics, and modeling analyses of the kinetics of serum tumor markers (EA 3738 CICLY). He is an active member of the French GINECO group, of the European ENGOT group, and of the international GCIG group.



Highlights:

- KELIM is the modeled CA-125 decline rate during the first 3 cycles of adjuvant or neo-adjuvant chemotherapy in first-line setting

- It is a pragmatic indicator of the tumor intrinsic chemosensitivity, easily calculable online on https://www.biomarker-kinetics.org

- KELIM is helpful to surgeons to anticipate the feasibility/complexity of complete interval debulking surgery after neo-adjuvant chemotherapy

- The analyses of ICON-7 and GOG-0218 trial datasets reproducibly showed that only the patients with unfavorable KELIM score < 1.0 had a survival benefit from bevacizumab among those with a high-risk disease

- KELIM may be a complementary tool to HRD status to select the best maintenance treatment in first-line setting, especially in patients with HRP cancer : PARP inhibitor expected to be effective in the case of favorable KELIM score ≥ 1.0 ; bevacizumab expected to be effective in the case of unfavorable KELIM score < 1.0